Much of the complexity of the cell and gene supply chain comes from how dependent the commercialization phase is on the clinical phase. What does integration look like, and how can the right logistics partner help?

How third-party logistics (3PL) solutions can help cell and gene therapy manufacturers manage the financial aspects of launching new therapies.

An executive Q&A on the role of data and the future of innovative reimbursement modeling for cell and gene therapies.

An executive Q&A on challenges and opportunities related to reimbursement, coding and coverage for cell and gene therapies.

How can manufacturers approach reimbursement and patient support for cell and gene therapies and other medical innovations?

In supply chain decisions, a wholly new type of product demands a wholly new definition for supply chain expertise and effective support.

Learn what it takes to design an effective commercialization strategy and execute an integrated solution when the patient is in the supply chain.